HUE028331T2 - N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás - Google Patents
N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás Download PDFInfo
- Publication number
- HUE028331T2 HUE028331T2 HUE03798156A HUE03798156A HUE028331T2 HU E028331 T2 HUE028331 T2 HU E028331T2 HU E03798156 A HUE03798156 A HU E03798156A HU E03798156 A HUE03798156 A HU E03798156A HU E028331 T2 HUE028331 T2 HU E028331T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- ser
- human
- leu
- peptide
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (7)
- hidÎ-CSONKOO' ß-AMILÖÖ> ELLENI MÖN0KLCE4ÁLÍI ELLEN ANYAGI, KÉSEÍTMENY, ELJÁRÁS ÈS ALKALMAZÁS Szabadalmi 8gé»y|m»tí>k t, Mooekletiâlis: dlenaayag, amelÿ specitikussn Mispmn aa ABlLMtérje <3teH-nàl BACH-l-gyel fortém hasítása «tán kapott Aßll-x pepiidet egyéb Akfoiragpiensékre adott kermzírsatóo. aéïfâl, ahol a ímmokkieáMS ellenanyag specifikusán folisæen «à {EsàdsïeiàzjLÎ hasítási hely «IsS 5-7 batöáte amiaosavät, mm a Seq Mbfo,:l és Saq là. No.;2 szerinti szekvenciát, vagy az ß-sBekreta;;Π hasítási hs% első 5-? sgéréradátii mmaôsavâh mm a Seq M bio.:3 és Seq U Hfofo szedné szekvenciát. Ί M L Igénypetst saersaÁ mpaokíoösiis ellenanyag, azzal jelkstezw, hogy áz Api 1A pepiid emberi Api 1-40.
- 3. Ás L vagy 2. igénypont szerinti ellenanyag, amely kim«talítstő modo« címkézett. 4, A 3. igénypont szenmi ellenanyag, ahol a ksnutatható eímfce mdioaktív jelölés, enzi®}efolé§, laaakesssceas jelölés vagy ttuoreszeens jelölés,
- 5, Az Id/igëaypostok bâiftïdyike szerinti eUeaaayag»-aaa^ly .feordözétt immoinikáli.
- 6. As I -S. igétrypontok hàmfoiyike szerinti ellenanyag, assoiym à Belgiaa Coordinated Collections of Mfcrootganteaas-nál 2003. angosztus \9'φ& rendié LMBP 5;#6CB ás LMBP 5897CB letéti szám«» letétbe helyeselt jMPRD/feAßl 3/1 ás MJPRDdxÄßil/2 htbndomaseitek Mpresszalsmk. %. A 20()2. augusztus IR-en a Belgian Coordinated Collections of Microorgamsms-ml rendre LMBP 5896CB és LMBP 5897CB: letéti számon létéibe helyezett I&JFRD/feApil/l és JMPRD/hAßU/2 hilmdómasejtek
- 8, Isununvizsgáiati módszer mtniabsö AFMshárje Clitl Bőéi BACEd-gyel történt hasítása után kapott Aßii-x pepiM meghatárosására vagy kimutatására, amely eljárás magában foglalja a minta érintkezietését 1-3. Igénypontok bármelyike szerinti, AßlLx pepiid elleni ellenanyaggal és annak meghatározását, bogf képződött' e komplex az ellenanyag; és az Aßl l-x peptid közöm % B||áíás szövetmintában AFF-febérjs Olull-aéi BACiE-l-gyél tânèni háshásá «ián kapott Aßl l-x pepttl! jelenlétének kimutatására, amely eljárás- magában foglalja a kővetkezőket: alahy iésfoffoi származó szőveímlma. édntkeztetése képalkotó eljárásban hatásos mennyiségű, 3. vagy 4. igénypont szériöít, kitntdathfoban uiíttkézeít ellenanyaggal, ás «..címke kknutaiása, ezáltal a szőveímmtáfean az Api 1 -x pepiid jeksiétáuek mégáüapitása. 19. A % igénypontszerinti eljárás, ahol a tómwiaih»tó «iodes címkézett ellenanyagi« a 6. igénypont szénné, legalább egyik bsbridómare.·t espresszálja
- 11. BÍíms tesífoiyssdékOiiíííábsn APF-Míé# Gla'l 1-náJ BACE-l-gye! tósléni hasítása mán kapott Aß| 1-X pepiid jelenlétének kímaiatására, aœ# «yáras magában fdgiaí|a a követelőket: alanjr testiből .gteató i«stíöl>nddkfp5«ía: árimkeztetáss képalkotó eljárásban hatásos mentsyiségá*· 3. vagy 41 igénypom szerinti, kte^^ltósít.stofc^ett4ite»aaya^:al, és scímke kíístitaldsa. ezáltal a testKslyaPokmístában az Mbi-x peptid jólonláténektnegáíainiása. i%. A 11, igénypont szerinti etjárás, almi a Mmoíatbalóa« CiöAégetíi eilemmyágot a ?. igénypont szerinti legalább egy tk éibrklémasejl: exprexszália,
- 13, M Eb, ígésypoPtok básöí&lyíke szeréi« «liena-iyag alkalmazása ß-anbioidbsi kapcsolatos betegség ín vkro diagnoszíszállsáza, 14; Diagnosztikai készítmény, aso# Wtátoaz 1-6. fénypontok bármelyike szcrM ellenanyagot és gyógjAszatilag el'fógadbató hordozót. iS, Ipipmhyjzsgslatra szolgáló készlet jhamiloiddai kapcsolatos betegség: diagrmsztizáiására, amely tanalmaz 2-S. igéoyponiöípbármslyike szénát! eSmaayagot és hordozol sz eilenääiysg szársíéra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/011062 WO2004029629A1 (en) | 2002-09-27 | 2002-09-27 | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028331T2 true HUE028331T2 (hu) | 2016-12-28 |
Family
ID=32039081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE03798156A HUE028331T2 (hu) | 2002-09-27 | 2003-09-09 | N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9329189B2 (hu) |
| EP (1) | EP1546734B1 (hu) |
| JP (3) | JP2006513988A (hu) |
| CN (2) | CN101367875B (hu) |
| AU (1) | AU2003266378B2 (hu) |
| CA (1) | CA2498058C (hu) |
| CY (1) | CY1117387T1 (hu) |
| DK (1) | DK1546734T3 (hu) |
| ES (1) | ES2560853T3 (hu) |
| HU (1) | HUE028331T2 (hu) |
| PT (1) | PT1546734E (hu) |
| SI (1) | SI1546734T1 (hu) |
| WO (2) | WO2004029629A1 (hu) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| EP1613657A2 (en) * | 2003-03-28 | 2006-01-11 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| BRPI0513959A (pt) | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| US20060246075A1 (en) * | 2004-09-29 | 2006-11-02 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
| ES2259270B1 (es) * | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| SG10201404801YA (en) | 2005-12-12 | 2014-09-26 | Ac Immune Sa | Monoclonal antibody |
| KR101263294B1 (ko) * | 2006-03-30 | 2013-06-04 | 글락소 그룹 리미티드 | 아밀로이드베타 펩티드에 대한 항체 |
| US20100028351A1 (en) * | 2006-06-29 | 2010-02-04 | Marc Mercken | Anti-amyloid antibodies, compositions, methods and uses |
| NZ574188A (en) * | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| PL2170389T3 (pl) * | 2007-06-12 | 2015-03-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| RS53174B (sr) * | 2007-10-05 | 2014-06-30 | Genentech Inc. | Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka |
| SG178809A1 (en) * | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
| EP2211886A4 (en) * | 2007-10-15 | 2011-07-27 | Centocor Ortho Biotech Inc | HUMAN ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, PROCESSES AND APPLICATIONS |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2222700A2 (en) * | 2007-11-27 | 2010-09-01 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| CN101463085B (zh) * | 2009-01-16 | 2011-09-14 | 清华大学 | 与A-beta寡聚体特异性结合的基因工程单克隆抗体 |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤 |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| BR112013023211B1 (pt) * | 2011-03-16 | 2022-11-08 | Vivoryon Therapeutics N.V. | Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| RU2017120039A (ru) | 2014-12-10 | 2019-01-10 | Дженентек, Инк. | Антитела к рецепторам гематоэнцефалического барьера и способы их применения |
| US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| CA3004494A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| JP7434144B2 (ja) | 2018-02-27 | 2024-02-20 | 株式会社島津製作所 | APP669-xのN末端を特異的に認識する抗体、及び免疫測定法 |
| US12311035B2 (en) | 2018-10-04 | 2025-05-27 | University Of Rochester | Glymphatic delivery by manipulating plasma osmolarity |
| AR117453A1 (es) | 2018-12-20 | 2021-08-04 | Genentech Inc | Fc de anticuerpos modificados y métodos para utilizarlas |
| EP3932942A4 (en) | 2019-03-01 | 2022-12-07 | Shimadzu Corporation | APP669-711 MEASUREMENT METHOD AND KIT |
| US20220268789A1 (en) | 2019-07-05 | 2022-08-25 | Shimadzu Corporation | Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| CN112540180B (zh) * | 2020-11-06 | 2022-03-29 | 华中科技大学 | 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2025250457A1 (en) | 2024-05-28 | 2025-12-04 | University Of Rochester | Enhanced brain transduction by gene therapeutics |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2006303A1 (en) * | 1997-04-09 | 2008-12-24 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof |
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| BRPI0108676B8 (pt) * | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
| AU2002243391A1 (en) | 2000-10-27 | 2002-06-24 | The Johns Hopkins University School Of Medicine | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| EP2731968A1 (en) * | 2011-07-15 | 2014-05-21 | Janssen Pharmaceutica NV | Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof |
-
2002
- 2002-09-27 WO PCT/EP2002/011062 patent/WO2004029629A1/en not_active Ceased
-
2003
- 2003-09-09 SI SI200332460T patent/SI1546734T1/sl unknown
- 2003-09-09 PT PT37981560T patent/PT1546734E/pt unknown
- 2003-09-09 ES ES03798156.0T patent/ES2560853T3/es not_active Expired - Lifetime
- 2003-09-09 CA CA2498058A patent/CA2498058C/en not_active Expired - Fee Related
- 2003-09-09 JP JP2004538886A patent/JP2006513988A/ja active Pending
- 2003-09-09 HU HUE03798156A patent/HUE028331T2/hu unknown
- 2003-09-09 US US10/528,928 patent/US9329189B2/en not_active Expired - Fee Related
- 2003-09-09 WO PCT/EP2003/010092 patent/WO2004029630A1/en not_active Ceased
- 2003-09-09 EP EP03798156.0A patent/EP1546734B1/en not_active Expired - Lifetime
- 2003-09-09 CN CN200810133343XA patent/CN101367875B/zh not_active Expired - Fee Related
- 2003-09-09 CN CNB038231166A patent/CN100418984C/zh not_active Expired - Fee Related
- 2003-09-09 AU AU2003266378A patent/AU2003266378B2/en not_active Ceased
- 2003-09-09 DK DK03798156.0T patent/DK1546734T3/en active
-
2014
- 2014-06-24 JP JP2014129164A patent/JP6420072B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-11 CY CY20161100112T patent/CY1117387T1/el unknown
- 2016-04-29 US US15/142,075 patent/US9939452B2/en not_active Expired - Fee Related
-
2017
- 2017-03-09 JP JP2017045114A patent/JP2017149719A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1081647A1 (zh) | 2006-05-19 |
| WO2004029629A1 (en) | 2004-04-08 |
| CA2498058A1 (en) | 2004-04-08 |
| AU2003266378A1 (en) | 2004-04-19 |
| DK1546734T3 (en) | 2016-02-08 |
| US9329189B2 (en) | 2016-05-03 |
| ES2560853T3 (es) | 2016-02-23 |
| PT1546734E (pt) | 2016-03-01 |
| WO2004029630A1 (en) | 2004-04-08 |
| CN101367875A (zh) | 2009-02-18 |
| EP1546734B1 (en) | 2015-11-11 |
| CN100418984C (zh) | 2008-09-17 |
| US9939452B2 (en) | 2018-04-10 |
| JP2017149719A (ja) | 2017-08-31 |
| AU2003266378B2 (en) | 2010-01-21 |
| JP2006513988A (ja) | 2006-04-27 |
| CY1117387T1 (el) | 2017-04-26 |
| SI1546734T1 (sl) | 2016-02-29 |
| CN101367875B (zh) | 2013-06-12 |
| JP6420072B2 (ja) | 2018-11-07 |
| US20060127954A1 (en) | 2006-06-15 |
| US20170192016A1 (en) | 2017-07-06 |
| JP2014208678A (ja) | 2014-11-06 |
| CA2498058C (en) | 2013-02-12 |
| EP1546734A1 (en) | 2005-06-29 |
| CN1685236A (zh) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1546734T3 (en) | MONOCLONAL ANTIBODIES AGAINST N-11-TRUNCATED AMYLOID BETA, COMPOSITIONS, PROCEDURES AND APPLICATIONS | |
| EP0683234B2 (en) | Antibody against beta-amyloid or their derivative and use thereof | |
| US10208111B2 (en) | Alpha-synuclein antibodies and uses thereof | |
| JP3115606B2 (ja) | βA4ペプチドに特異的なモノクローナル抗体 | |
| US5955317A (en) | Antibodies to β-amyloids or their derivatives and use thereof | |
| JP3553592B2 (ja) | 可溶性β−アミロイド・ペプチドの検出のための方法及び組成物 | |
| EP2189526B1 (en) | Antibody binding specifically to tdp-43 aggregate | |
| US7807157B2 (en) | Monoclonal antibodies and use thereof | |
| US5985581A (en) | Use of presenilin-1 for diagnosis of alzheimers disease | |
| EP0655626A1 (en) | Diagnostic assays for Alzheimer's disease | |
| JP4374316B2 (ja) | β−アミロイドまたはその誘導体に対する抗体およびその用途 | |
| JP2955082B2 (ja) | ヒトカルシトニンのn末端部分を特異的に認識するモノクローナル抗体 | |
| JP4037933B2 (ja) | 抗ヒトカルシトニンモノクローナル抗体 | |
| JP2014520825A (ja) | モノクローナル抗体に対して特異的なβ−アミロイドx−37およびその使用 | |
| HK1081647B (en) | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses | |
| HK1126797A (en) | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses | |
| HK1217107B (en) | Alpha-synuclein antibodies and uses thereof | |
| JPWO1994017197A1 (ja) | β−アミロイドまたはその誘導体に対する抗体およびその用途 |